

[17] Ferriss JS, Java JJ, Bookman MA, et al. Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: an NRG Oncology/GOG study [J]. Gynecol Oncol, 2015, 139: 17-22.

[18] Oza AM, Cook AD, Pfisterer J, et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial [J]. Lancet Oncol, 2015, 16: 928-936.

[19] Symonds RP, Gourley C, Davidson S, et al. Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial [J]. Lancet Oncol, 2015, 16: 1515-1524.

[20] Trimble CL, Morrow MP, Kraynyak KA, et al. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial [J]. Lancet, 2015, 386: 2078-2088.

[21] Chan JL, Letourneau J, Salem W, et al. Sexual satisfaction and quality of life in survivors of localized cervical and ovarian cancers following fertility-sparing surgery [J]. Gynecol Oncol, 2015, 139: 141-147.

[22] Melin J, Heinavaara S, Malila N, et al. Adverse Obstetric Outcomes Among Early-Onset Cancer Survivors in Finland [J]. Obstet Gynecol, 2015, 126: 803-810.

[23] Felix AS, Scott McMeekin D, Mutch D, et al. Associations between etiologic factors and mortality after endometrial cancer diagnosis: The NRG Oncology/Gynecologic Oncology Group 210 trial [J]. Gynecol Oncol, 2015, 139: 70-76.

[24] Pol FJM, Zusterzeel PLM, van Ham MAPC, et al. Satellite lymphovascular space invasion: An independent risk factor in early stage cervical cancer [J]. Gynecol Oncol, 2015, 138: 579-584.

[25] Andersen CL, Eskelund CW, Siersma VD, et al. Is thrombocytosis a valid indicator of advanced stage and high mortality of gynecological cancer? [J]. Gynecol Oncol, 2015, 139: 312-318.

(收稿日期: 2015-12-28)

· 医学新闻 ·

郎景和院士被任命为 2016—2017 年度美国腹腔镜医师协会 亚太地区理事

在 2015 年 11 月 6 日举办的“第十六届亚太妇产科内视镜及微创治疗医学会学术年会暨中华医学会第七次全国妇科内镜及微创诊疗学术会议”上，北京协和医院郎景和院士被任命为 2016—2017 年度美国腹腔镜医师协会（Americam Association of Gynecologic Laparoscopists, AAGL）亚太地区理事，充分展现了我国妇产科学界在亚太地区的领导地位和号召力。

AAGL 是全球知名的妇科内镜学术组织，在全球

有非常深远的影响力。AAGL 成立于 1971 年，1972 年第一届 AAGL 会议在拉斯维加斯召开，以后每年召开一次，会议代表来自世界各地，代表国际最先进的内镜技术水平。中国于 2002 年成为其会员国，这对向世界介绍中国的内镜技术及促进国际交流有重要意义。

(北京协和医院宣传处 郭 晶)